Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2020 | MRD: Paving the way for future clinical trials in myeloma

Francesca Gay • 14 Dec 2020
ASH 2020
Multiple Myeloma
FORTE

Francesca Gay, MD, PhD, University of Turin, Turin, Italy, highlights the importance of using measurable residual disease (MRD) measurements as predictors of outcomes in newly diagnosed multiple myeloma. She discusses how MRD should be utilized in clinical trials to modulate treatment according to MRD status in the near future. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

More from Francesca Gay

An insight into designing randomized studies in high-risk myeloma
Binod Dhakal et al. • 4 Nov 2024
FORTE: MRD by MFC or NGS in myeloma 1:46
FORTE: MRD by MFC or NGS in myeloma
Francesca Gay • 14 Dec 2020
FORTE: KRd versus KCd treatment for myeloma 0:45
FORTE: KRd versus KCd treatment for myeloma
Francesca Gay • 14 Dec 2020
MRD evaluation by MFC and NGS for MM 1:06
MRD evaluation by MFC and NGS for MM
Francesca Gay • 7 Dec 2019

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals